AVITA MEDICAL WKN: A0Q40S ISIN: AU000000AVH4 Kürzel: AVMXF Forum: Aktien Thema: Hauptdiskussion

AVITA Medical Rejoins the Russell 3000 Index https://www.globenewswire.com/news-release/2023/06/26/2694404/0/en/AVITA-Medical-Rejoins-the-Russell-3000-Index.html

AVITA scores US FDA approval for vitiligo treatment https://www.businessnewsaustralia.com/articles/avita-scores-us-fda-approval-for-vitiligo-treatment.html

AVITA Medical Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients https://www.globenewswire.com/news-release/2023/06/16/2689906/0/en/AVITA-Medical-Announces-FDA-Approval-of-RECELL-for-Skin-Repigmentation-in-Vitiligo-Patients.html

Da fehlt aber noch die Zulassung für vitiligo oder?

👍 hört sich schon mal gut an

AVITA Medical Announces FDA Approval of RECELL for Treatment of Full-Thickness Skin Defects https://www.businessupturn.com/brand-post/avita-medical-announces-fda-approval-of-recell-for-treatment-of-full-thickness-skin-defects/

AVITA Medical Reports First Quarter Financial Results and Affirms Full Year Guidance https://ir.avitamedical.com/news-releases/news-release-details/avita-medical-reports-first-quarter-financial-results-and

Wann rechnet ihr mit den Zulassungen die im dritten Quartal 23 eingeführt werden sollen?

AVITA Medical Announces Update to Automation Device https://www.globenewswire.com/news-release/2023/04/13/2646762/0/en/AVITA-Medical-Announces-Update-to-Automation-Device.html

Kurseinbruch auf SVB Pleite zurückzuführen oder gab es andere news?

https://hotcopper.com.au/threads/ann-s-p-dji-announces-march-2023-quarterly-rebalance.7266043/

https://www.globenewswire.com/news-release/2023/02/27/2616077/0/en/AVITA-Medical-to-Host-Investor-Webinar-Briefing.html

https://finance.yahoo.com/news/brokers-upgrading-views-avita-medical-002043398.html

👍

🍀

AVITA Medical GAAP EPS of -$0.21 beats by $0.07, revenue of $9.46M beats by $0.63M https://seekingalpha.com/news/3940180-avita-medical-gaap-eps-of-0_21-beats-0_07-revenue-of-9_46m-beats-0_63m • AVITA Medical press release (NASDAQ:RCEL): Q4 GAAP EPS of -$0.21 beats by $0.07. • Revenue of $9.46M (+36.3% Y/Y) beats by $0.63M. • Our commercial revenue, which excludes BARDA revenue, increased by 37% to $9.4 million in the three months ended December 31, 2022, compared to $6.8 million in the same period in 2021.